Skip to content

News

Study Shows Survival Advantage of Primary Cytoreductive Sur...

Study Shows Survival Advantage of Primary Cytoreductive Surgery

(April 26, 2018) The International Journal of Gynecological Cancer recently featured a retrospective study on the treatment patterns of women with advanced high-grade serous ovarian carcinoma (HGSC). Of the 852 women with HGSC included in the study, 53% of them underwent primary cytoreductive surgery (PCS), or surgery before chemotherapy to remove as much of the tumor … Continued

Research

OCRFA Funded Study Explores Implant that Detects Ovarian Ca...

OCRFA Funded Study Explores Implant that Detects Ovarian Cancer Biomarker

(April 24, 2018) Science Advances recently published a study that succeeded in detecting HE4, a biomarker for high-grade serous ovarian cancer (HGSC), by implanting an optical sensor near a disease site in mice. HE4, like CA-125, is approved by the U.S. Food and Drug Administration as a biomarker for HGSC. However, these biomarkers are more … Continued

OCRA News

Register for OCRFA’s Ovarian Cancer National Conferen...

Register for OCRFA’s Ovarian Cancer National Conference on July 13-15 in Washington, DC

Join ovarian cancer survivors, caregivers, researchers and healthcare providers at OCRFA’s Ovarian Cancer National Conference – an informative and transformative weekend of hope, inspiration and fun. Get a front row seat at expert plenary and breakout sessions, from the newly-expanded Ask the Experts, to sessions on understanding PARP inhibitors, and sexual health after cancer. Learn … Continued

Events

Vaccine for Ovarian Cancer Shows Promising Results in Pilot...

Vaccine for Ovarian Cancer Shows Promising Results in Pilot Trial

(April 17, 2018) Science Translational Medicine recently published a University of Pennsylvania Perelman School of Medicine/University of Lausanne, Switzerland study on using a patient’s immune system to fight their cancer. In this pilot trial, 25 patients with advanced epithelial recurrent ovarian cancer were either given the vaccine alone, with the chemotherapy drug bevacizumab, or a … Continued

Research

Join us for an intimate evening of tastings at Turn Up the ...

Join us for an intimate evening of tastings at Turn Up the Heat Boston

A tantalizing menu of irresistible treats, crafted by the region’s top female chefs, mixologists and restaurateurs, awaits you at Boston College Club on May 8th. Indulge to your heart’s delight, and be sure to save room for rich chocolate buttermilk cake with dark chocolate ganache, courtesy of Pastry Chef Mareena McKenzie of Strip-T’s. Mareena was … Continued

Events

FDA Approves Rucaparib as Maintenance Treatment for Platinu...

FDA Approves Rucaparib as Maintenance Treatment for Platinum Sensitive Recurrent Ovarian Cancer

(April 10, 2018) Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have had at least a partial response to platinum based chemotherapy have a new, FDA approved option for maintenance therapy. The evidence that led to the FDA approving rucaparib comes from the phase 3 ARIEL3 clinical trial, which enrolled 564 … Continued

Research

Updates from 2018 Annual Meeting on Women’s Cancer

Updates from 2018 Annual Meeting on Women’s Cancer

(April 4, 2018) It’s an exciting time for ovarian cancer research! Ovarian cancer clinicians, researchers and advocates came together in New Orleans at the end of March for the Annual Meeting on Women’s Cancer, hosted by the Society of Gynecologic Oncology (SGO). Meeting attendees learned about the latest developments in ovarian cancer research, treatment, and … Continued

Research

Genetic Counseling and Testing by Oncologists Feasible for ...

Genetic Counseling and Testing by Oncologists Feasible for Ovarian Cancer Patients

(April 3, 2018) A study in the Journal of Clinical Oncology explored the effects of oncologists, rather than genetic counselors, testing ovarian cancer patients for BRCA mutations. Due to the limited number of genetic counselors and the increase in demand for BRCA mutation testing, ovarian cancer patients don’t always have the ability or opportunity to … Continued

Research

Statement from OCRFA President & CEO Audra Moran on th...

Statement from OCRFA President & CEO Audra Moran on the Death of U.S. Representative Louise Slaughter

(March 16, 2018) On behalf of Ovarian Cancer Research Alliance I want to extend our deepest condolences on the passing of U.S. Representative Louise Slaughter. As the author of the landmark Genetic Information Nondiscrimination Act (GINA), signed into law in 2008 after a 14-year battle, Representative Slaughter proved to be a tireless advocate for patients … Continued

OCRA News

Discovery of New Gene Mutation That Increases Ovarian Cance...

Discovery of New Gene Mutation That Increases Ovarian Cancer Risk, Passed Down Through Paternal Lineage

(February 22, 2018) Researchers at Roswell Park Comprehensive Cancer Center, including Kunle Odunsi, MD, PhD, senior author of the study and current OCRFA Scientific Advisory Committee member, have discovered a mutation of an unidentified gene that increases both the risk of early onset ovarian cancer and prostate cancer. Using the Familial Ovarian Cancer Registry at … Continued

OCRA News

US Preventive Services Task Force: Ovarian Cancer Screening...

US Preventive Services Task Force: Ovarian Cancer Screening Not Effective for Low-Risk Women

(February 14, 2018) Today the US Preventive Task Force updated their recommendation on ovarian cancer screening, reaffirming their 2012 position that screening average risk women for ovarian cancer is not effective in reducing mortality from the disease. Furthermore, they stated that screening for ovarian cancer carries certain risk and harms that may be substantial, and … Continued

Research

World Cancer Day is February 4

World Cancer Day is February 4

On World Cancer Day, the world comes together to defeat cancer. Ovarian cancer is a worldwide disease. The cure starts right here. At OCRFA, we’re making progress every day toward a world without ovarian cancer. We’re funding top scientists performing the most innovative research in the field. We’re helping women and their families face challenges … Continued

Community

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.